共 64 条
[1]
Eder M(2014)Novel preclinical and radiopharmaceutical aspects of [68 Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer Pharmaceuticals (Basel) 7 779-796
[2]
Neels O(2014)Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer Eur J Nucl Med Mol Imaging 41 11-20
[3]
Muller M(2015)The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer Eur J Nucl Med Mol Imaging 42 197-209
[4]
Afshar-Oromieh A(2016)Pilot comparison of (6)(8)Ga-RM2 PET and (6)(8)Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer J Nucl Med 57 557-562
[5]
Zechmann CM(2018)Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT J Nucl Med 59 469-478
[6]
Malcher A(2015)Evaluation of hybrid (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy J Nucl Med 56 668-674
[7]
Afshar-Oromieh A(2013)PET imaging with a [ Eur J Nucl Med Mol Imaging 40 486-495
[8]
Avtzi E(2015)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions Eur J Nucl Med Mol Imaging 42 1284-1294
[9]
Giesel FL(1995)(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Urol Oncol 1 18-28
[10]
Minamimoto R(2004)Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues Histol Histopathol 19 715-718